BioSpace News Archive

Biomind Labs Inc. (“Biomind Labs” or the “Company”) (NEO: BMND) (OTC: BMNDF) (FSE: 3XI) is pleased to announce the successful completion of the first 5-Metoxi-N,N-dimethyltryptamine (“5-MeO-DMT”) organic synthesis scheme.

MAPS Public Benefit Corporation (“MAPS PBC”) announced that data from the company’s MAPP2 clinical trial, a multi-site Phase 3 study of MDMA-assisted therapy for post–traumatic stress disorder (“PTSD”), was published in the September issue of Nature Medicine.

Curasight A/S (“Curasight” or the “Company” - TICKER: CURAS) announces today that the previously announced results from the investigator-initiated phase II study using uPAR-PET (uTRACE®) in primary brain cancer have been presented in an oral presentation at the World Molecular Imaging Congress (WMIC) 2023 in Prague.

Automated Control Concepts, a leading innovator in biotechnology solutions, announced the next release of its cutting-edge bioreactor control and data platform, Lab Owl, with new advancements that promise to redefine the landscape of bioprocessing.

Optimi Health Corp. (CSE: OPTI) (OTCQX: OPTHF) (FRA: 8BN), a Canadian psychedelics drug research and formulation company, is pleased to see the positive and encouraging outcomes from the MAPS Phase 3 MDMA-Assisted Therapy (MDMA-AT) Clinical Trial published today on Nature Medicine.

Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a neurology-focused biopharmaceutical company, today announced that the company will present at TD Cowen’s 3rd Annual Novel Mechanisms in Neuropsychiatry Summit to be held on September 20, 2023.

Pasithea Therapeutics Corp. today announced the final results of its previously announced tender offer to acquire up to 5,714,285 shares of its common stock, par value $0.0001 per share, at a price of $0.70 per share.

ProSomnus, Inc. (NASDAQ: OSA ), a leading CPAP alternative for the treatment of Obstructive Sleep Apnea (“OSA”), today announced that their precision sleep apnea devices will be prominently featured in the scientific programs at upcoming medical conferences.

Moleculin Biotech, Inc. today announced its abstract has been accepted for poster presentation at the 2023 CTOS Annual Meeting being held November 1-4, 2023 in Dublin, Ireland.

Altamira Therapeutics Ltd. (Nasdaq:CYTO), a company dedicated to developing therapeutics that address important unmet medical needs, today announced further positive and statistically significant efficacy data from the randomized controlled NASAR clinical trial, which evaluated their Bentrio nasal spray in seasonal allergic rhinitis (SAR).